Cholesterol → Epirubicin Hydrochloride

HRID 249234

반응식

HRID 249234 반응식
CCCCCCCC/C=C/CCCCCCCC(OCC(OC(CCCCCCC/C=C/CCCCCCCC)=O)COP(OCCNC(CCC(OCCOC)=O)=O)(O)=O)=O.CC(CCC[C@H]([C@@H]1[C@]2(C)[C@H]([C@H]3[C@H](CC2)[C@]2(C)C(C[C@H](CC2)O)=CC3)CC1)C)C.[CH3:91][C@@H:92]1[O:97][C@@H:96]([O:98][C@@H:99]2[C:104]3=[C:105]([OH:122])[C:106]4[C:118](=[O:119])[C:117]5[C:112](=[CH:113][CH:114]=[CH:115][C:116]=5[O:120][CH3:121])[C:110](=[O:111])[C:107]=4[C:108]([OH:109])=[C:103]3[CH2:102][C@@:101]([OH:127])([C:123]([CH2:125][OH:126])=[O:124])[CH2:100]2)[CH2:95][C@H:94]([NH2:128])[C@H:93]1[OH:129].C(Cl)(Cl)[Cl:131]>>[CH3:91][C@@H:92]1[O:97][C@@H:96]([O:98][C@@H:99]2[C:104]3=[C:105]([OH:122])[C:106]4[C:118](=[O:119])[C:117]5[C:112](=[CH:113][CH:114]=[CH:115][C:116]=5[O:120][CH3:121])[C:110](=[O:111])[C:107]=4[C:108]([OH:109])=[C:103]3[CH2:102][C@@:101]([OH:127])([C:123]([CH2:125][OH:126])=[O:124])[CH2:100]2)[CH2:95][C@H:94]([NH2:128])[C@H:93]1[OH:129].[ClH:131].[CH3:91][C@@H:92]1[O:97][C@@H:96]([O:98][C@@H:99]2[C:104]3=[C:105]([OH:122])[C:106]4[C:118](=[O:119])[C:117]5[C:112](=[CH:113][CH:114]=[CH:115][C:116]=5[O:120][CH3:121])[C:110](=[O:111])[C:107]=4[C:108]([OH:109])=[C:103]3[CH2:102][C@@:101]([OH:127])([C:123]([CH2:125][OH:126])=[O:124])[CH2:100]2)[CH2:95][C@H:94]([NH2:128])[C@@H:93]1[OH:129].[ClH:131]

참가 물질

6

반응물 4

HCID 5997CholesterolHCID 6212ChloroformHCID 41867EpirubicinHCID 6440842[3-[hydroxy-[2-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]ethoxy]phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate

생성물 2

HCID 65348Epirubicin HydrochlorideHCID 443939Doxorubicin Hydrochloride

실험 절차

Vesicle-forming lipids containing PEG-PE, PG, PHEPC, and cholesterol and α-TC in a mole ratio of 0.15: 0.3: 1.85: 1: 0.2 were dissolved in chloroform to a final lipid concentration of 25 μmol phospholipid/ml. The lipid mixture was dried into a thin film under reduced pressure. The film was hydrated with a solution of 0.125 M ammonium sulfate to form MLVs. The MLV suspension was frozen in a dry ice acetone bath and thawed three times and sized to 80-100 nm by extrusion as detailed above. An ammonium ion gradient was created substantially as described in Example 10. The liposomes were loaded with epirubicin, and free (unbound drug) removed also as described in Example 10 for doxorubicin. The final concentration of entrapped drug was about 50-100 μg drug/μmol lipid. Epirubicin HCl and doxorubicin HCL, the commercial products, were obtained from the hospital pharmacy.

후처리

  1. customVesicle-forming lipids
  2. customThe lipid mixture was dried into a thin film under reduced pressure
  3. customto form MLVs
  4. temperatureThe MLV suspension was frozen in a dry ice acetone bath
  5. customremoved also

출처 및 근거

ORD 기록
ord-a8c09ad378a649a4bf286246ad752077
출처 데이터셋
uspto-grants-1993_05
특허 번호
US05213804

연결된 노트

불러오는 중…